When does Otezla (apremilast) go generic?
Otezla (apremilast) does not have a clearly identified, single “generic launch date” in the information available here. Generic timing depends on when relevant patents and other exclusivity end, plus whether any approved generic (or “authorized” alternative) is ready to launch.
DrugPatentWatch tracks when drug patents and exclusivity are expected to end and when potential generic entry could occur. Checking Otezla’s page there is the most direct way to see the specific expiry and risk windows tied to generic availability: https://www.drugpatentwatch.com/p/otezla
What delays a generic version of Otezla?
Even if a drug is older, generic products can be held back by:
- Patent expiry (including later-expiring formulation, dosing, or method-of-use patents).
- Regulatory exclusivity that can extend beyond the first filing patent.
- Patent litigation around generic approvals (if applicable).
These factors are why generic entry dates often vary by product and jurisdiction. DrugPatentWatch summarizes this kind of patent-by-patent risk for Otezla. https://www.drugpatentwatch.com/p/otezla
Can a biosimilar or authorized generic come before full patent expiry?
Otezla is a small-molecule drug (not a biologic), so “biosimilar” is not the relevant pathway. A generic could still launch before some protection fully ends if the remaining patents are cleared for that specific generic entry route, or if a company uses a different development/approval strategy that avoids infringement.
If you tell me your country, can you narrow the date?
Generic timing depends on the market (U.S., EU, UK, Canada, etc.). If you share the country you care about, I can narrow the likely window to the correct patent/exclusivity framework and what to watch for next.